Plant Arginine Mimic Canavanine Disrupts Cancer Cell Metabolism and Signals

Colorectal carcinoma remains one of the most challenging malignancies to treat, and researchers continue to search for metabolic vulnerabilities that can be exploited therapeutically. One of the more intriguing strategies to emerge in recent years is arginine deprivation therapy, an approach that starves tumor cells of the semi-essential amino acid arginine. Many cancer cells lose the ability to synthesize arginine from its precursors, making them exquisitely dependent on an external supply. A new study from researchers at the Institute of Cell Biology of the National Academy of Sciences of Ukraine, with a collaborator at the Luxembourg Institute of Health, published in Cancer Cell International, now reveals how a plant-derived arginine mimic called canavanine interacts with the stress pathways that arginine starvation triggers in colorectal carcinoma cells, opening potential new avenues for combination treatment.

The research team focused on canavanine, a naturally occurring structural analogue of L-arginine found in certain legumes such as jack bean. Because canavanine closely resembles arginine in shape and charge, cells can mistakenly incorporate it into proteins in place of arginine, a process that produces malformed, dysfunctional proteins and ultimately cytotoxicity. This property has long made canavanine an object of interest in cancer research, but its precise effects on the regulatory circuitry of arginine metabolism had remained incompletely understood. The new work demonstrates that canavanine does far more than simply poison protein synthesis; it actively participates in the cellular signaling networks that govern how tumor cells sense and respond to arginine availability.

Central to the study is argininosuccinate synthetase 1, or ASS1, an enzyme of the urea cycle that catalyzes the rate-limiting step in the conversion of citrulline and aspartate into argininosuccinate, a precursor of arginine. ASS1 expression is a key determinant of whether a cancer cell can survive arginine deprivation therapy. Tumors with low or silenced ASS1 cannot make their own arginine and are therefore vulnerable to enzymes such as recombinant human arginase 1 or arginine deiminase, which deplete circulating arginine. Conversely, tumors that retain robust ASS1 expression can adapt to arginine starvation by synthesizing the amino acid from citrulline, rendering deprivation therapy ineffective. Understanding what controls ASS1 expression under conditions of arginine stress is therefore of substantial clinical relevance.

Using colorectal carcinoma cell lines cultivated in both complete medium and arginine-free medium, the investigators systematically examined how canavanine affects cellular signaling and gene regulation. Their most striking finding was that canavanine represses transcription of the ASS1 gene in colorectal carcinoma cells subjected to arginine starvation. In other words, the plant mimic does not merely stand in for arginine in protein synthesis; it also mimics arginine’s role in the regulatory pathways that shut down arginine biosynthesis when the cell senses sufficient arginine supply. This feedback-like behavior, now triggered by a drug-like compound, could deepen the metabolic deficit that arginine deprivation therapy is designed to create.

Intriguingly, the researchers established that this repression of ASS1 occurs in a c-Myc-independent manner. The transcription factor c-Myc has been implicated in the regulation of metabolic genes, including components of the urea cycle, in several cancer contexts, and one might have expected its involvement here. The finding that canavanine-mediated ASS1 silencing proceeds without c-Myc suggests that alternative regulatory mechanisms, possibly involving other transcriptional repressors or epigenetic modifications, are at play. This distinction matters because it points to previously unappreciated control points in the arginine metabolic network that could be targeted pharmacologically to sensitize tumors to deprivation therapy.

Beyond gene regulation, the study documented that canavanine dysregulates broader cellular signaling pathways in the stressed colorectal carcinoma cells. The authors observed effects consistent with the compound mimicking arginine in several regulatory routes, echoing behaviors previously described for other arginine analogues such as indospicine, thioarginine, and homoarginine, which the team considered in framing their experimental design. Analogues of amino acids have historically served as powerful probes of cellular metabolism precisely because they infiltrate the same transport, biosynthetic, and regulatory systems as their natural counterparts. By mapping which signaling nodes respond to canavanine under arginine starvation, the study provides a molecular picture of how tumor cell physiology unravels when arginine homeostasis is doubly compromised, first by external deprivation and then by internal mimicry.

Perhaps the most therapeutically consequential observation is that pre-exposure to arginine deprivation additionally sensitizes colorectal carcinoma cells to the cytotoxic effects of canavanine. Cells that were first grown in arginine-free conditions became more vulnerable to subsequent canavanine treatment than cells maintained in complete medium. This sequencing effect suggests that arginine starvation primes tumor cells, weakening their metabolic flexibility and protein synthesis machinery, so that the counterfeit amino acid inflicts maximal damage once it is introduced. Clinically, this raises the possibility of rational combination and sequential regimens in which an arginine-degrading enzyme is administered first, followed by canavanine, to achieve a two-step metabolic assault that tumor cells cannot easily withstand.

The findings may help resolve two persistent shortcomings of arginine deprivation therapy. The first is resistance: tumors that maintain ASS1 expression can escape starvation by producing arginine from citrulline, and some tumors upregulate ASS1 adaptively under treatment pressure. A compound that actively represses ASS1 transcription, as canavanine does under arginine-free conditions, could counteract this adaptive route and keep the metabolic door closed. The second shortcoming is incomplete efficacy as a monotherapy, which has motivated the search for combinations. The demonstration that deprivation pre-exposure potentiates canavanine cytotoxicity offers an evidence-based rationale for scheduling these agents together, a strategy that could extend to cancers beyond colorectal carcinoma, including entities such as melanoma and hepatocellular carcinoma that have been evaluated for arginine dependency.

The work also carries broader scientific significance for the field of cancer metabolism. It illustrates that a single metabolite analogue can simultaneously act at multiple levels, substituting for arginine during translation, perturbing signal transduction, and reshaping the transcriptional landscape of metabolic genes. This pleiotropy underscores the dense interconnection between nutrient sensing, protein homeostasis, and gene expression in tumor cells. Moreover, because ASS1 silencing in many tumors occurs through epigenetic mechanisms such as promoter methylation, the observation that canavanine can drive ASS1 downregulation in a c-Myc-independent way invites further investigation into whether amino acid availability itself, and arginine mimics in particular, can shape the epigenetic state of metabolic genes during therapy.

The study, conducted by G. Y. Shuvayeva, Y. P. Bobak, O. I. Chen, O. I. Vovk, and O. V. Stasyk, is available as an open access article, allowing clinicians, cancer biologists, and metabolic researchers worldwide to examine the data in full. While the experiments were performed in vitro and will require validation in preclinical models before any translational application, they provide a compelling mechanistic foundation for combining arginine deprivation with canavanine in metabolic therapeutic modalities for colorectal carcinoma and potentially other ASS1-deficient cancers. As arginine deprivation therapy continues to be evaluated across a number of tumor entities, this work adds a molecularly grounded rationale for the next generation of combination strategies aimed at starving tumors of the amino acids they can no longer live without.

Subject of Research: Effects of canavanine on cellular signaling and ASS1 expression in colorectal carcinoma cells under arginine deprivation

Article Title: Canavanine dysregulates cellular signaling and represses ASS1 under arginine deprivation in colorectal carcinoma cells

Article References: Shuvayeva, G. Y., Bobak, Y. P., Chen, O. I., Vovk, O. I., & Stasyk, O. V. (2026). Canavanine dysregulates cellular signaling and represses ASS1 under arginine deprivation in colorectal carcinoma cells. Cancer Cell International. https://doi.org/10.1186/s12935-026-04450-9

Image Credits: AI Generated

DOI: 10.1186/s12935-026-04450-9

Keywords: arginine deprivation therapy, canavanine, ASS1, colorectal carcinoma, cancer metabolism, argininosuccinate synthetase, urea cycle, c-Myc, chemotherapy, amino acid analogue, cancer therapy, metabolic treatment